Loading...
•
Jun 30, 2025
Day One Q2 2025 Earnings Report
Day One Biopharmaceuticals reported its second quarter 2025 financial results, highlighting strong revenue growth for OJEMDA and progress in its clinical pipeline.
Key Takeaways
Day One Biopharmaceuticals demonstrated strong performance in Q2 2025, primarily driven by significant growth in OJEMDA net product revenue, which increased by 310% year-over-year. The company ended the quarter with a solid cash position and is on track with its clinical development programs, including the pivotal Phase 3 FIREFLY-2 trial.
OJEMDA net product revenue reached $33.6 million in Q2 2025, marking a 310% increase from Q2 2024.
OJEMDA prescriptions exceeded 1,000 in Q2 2025, representing a 15% quarter-over-quarter increase.
The company maintained a strong financial position with $453.1 million in cash, cash equivalents, and short-term investments as of June 30, 2025.
Enrollment for the pivotal Phase 3 FIREFLY-2 clinical trial is on track for completion in the first half of 2026.
Revenue by Segment
Forward Guidance
Day One Biopharmaceuticals expects full-year 2025 net product revenue for OJEMDA to be between $140 million and $150 million. The company is also progressing with its clinical trials, with key data presentations and trial completion expected in the coming quarters.
Positive Outlook
- OJEMDA full-year 2025 net product revenue expected to be $140 to $150 million.
- DAY301 Phase 1a/b clinical trial is actively enrolling patients and progressing as planned.
- Expects to present 3-year follow-up data from the FIREFLY-1 clinical trial in Q4 2025.
- Patient enrollment in the pivotal Phase 3 FIREFLY-2 clinical trial is on track to achieve completion in the first half of 2026.
- Strong financial foundation with $453.1 million in cash, cash equivalents and short-term investments.
Challenges Ahead
- No specific negative forward guidance was provided in the report.
- The company terminated its research collaboration and license agreement with Sprint Bioscience AB for the VRK1 program.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...